The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs

AIDS

Volumn 26, Issue 16, 2012, Pages 2069-2078

  Li, Jinghua ^a,b   Gilmour, Stuart ^a   Zhang, Haiqiang ^c   Koyanagi, Ai ^a   Shibuya, Kenji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

China; cost effectiveness analysis; drug users; HIV AIDS; mathematical models

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; EPIDEMIC; HARM REDUCTION; HEALTH PROGRAM; HIGH RISK POPULATION; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; NEEDLE; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEXUAL INTERCOURSE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHINA; COST-BENEFIT ANALYSIS; COUNSELING; DISEASE PROGRESSION; FEMALE; HARM REDUCTION; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84867741247     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283574e54     Document Type: Article

References (37)

1. Ministry of Health of China. China 2010 UNGASS Country Progress Report (2008-2009). Beijing, China: Ministry of Health of China; 2010.
2. National Bureau of Statistics of China. 2010 China Health Statistical Yearbook. Beijing, China: National Bureau of Statistics of China; 2010.
3. UNAIDS. 2008 Report on the global aids epidemic. Geneva, Switzerland: UNAIDS; 2008.
4. Wang L, Wang N, Li D, Jia M, Gao X, Qu S, et al. The 2007 estimates for people at risk for and living with HIV in China: progress and challenges. J Acquir Immune Defic Syndr 2009; 50:414-418.
5. Ma X, Zhang Q, He X, Sun W, Yue H, Chen S, et al. Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men. Results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. J Acquir Immune Defic Syndr 2007; 45:581-587.
6. Cao X, Yin W, Pang L, Zhang C, Xu J, Xiao Y, et al. Risk factors which were associated with heroin use during the methadone maintenance treatment among 1301 patients in 9 cities of China. Chin J Epidemiol 2010; 31:269-272.
7. Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, Poundstone K, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. Sex Transm Infect 2006; 82 (Suppl 3):iii87-iii91.
8. Guo H, Wei JF, Yang H, Huan X, Tsui SK, Zhang C. Rapidly increasing prevalence of HIV and syphilis and HIV-1 subtype characterization among men who have sex with men in Jiang-su, China. Sex Transm Dis 2009; 36:120-125.
9. Ruan S, Yang H, Zhu Y, Wang M, Ma Y, Zhao J, et al. Rising HIV prevalenceamongmarriedandunmarriedamongmenwhohave sex with men: Jinan, China. AIDS Behav 2009; 13:671-676.
10. Feng L, Ding X, Lu R, Liu J, Sy A, Ouyang L, et al. High HIV prevalence detected in 2006 and 2007 among men who have sex with men in China's largest municipality: an alarming epidemic in Chongqing, China. J Acquir Immune Defic Syndr 2009; 52:79-85.
11. NCHECR. Return on investment 2: evaluating the cost effectiveness of needle syringe programs in Australia. Darlinghurst, NSW, Australia: NCHECR, Department of Health and Ageing; 2009.
12. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008; 372:669-684.
13. McClelland RS, Graham SM, Richardson BA, Peshu N, Masese LN, Wanje GH, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS 2010; 24:891-897.
14. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
15. Cleary PD, Van Devanter N, Rogers TF, Singer E, Shipton-Levy R, Steilen M, et al. Behavior changes after notification of HIV infection. Am J Public Health 1991; 81:1586-1590.
16. Higgins DL, Galavotti C, O'Reilly KR, Schnell DJ, Moore M, Rugg DL, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991; 266:2419-2429.
17. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
18. UNAIDS. 2006 Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2006.
19. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antire-troviral treatment in the United States. Ann Intern Med 2010; 153:778-789.
20. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: WHO; 2003.
21. WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva, Switzerland: WHO; 2001.
22. Li X, Tan H, Sun Z, Zhang H, Chen M, Ou Q. Study on the time of retention and related infuluencing factors of patients receiving methadone maintenance treatment in Hunan province. Chin J Epidemiol 2009; 30:672-675.
23. Luo W, Pang L, Wu Z, Mi G, Wang C, Li J. Enrollment and retention rate of patients in the first batch of methadone maintenance clinics in China. Chin Ment Health J 2007; 21:478-480.
24. Vickerman P, Watts C. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. Int J Drug Policy 2002; 13:149-164.
25. Cheng G, Qian Z, Hu J. Longitudinal analysis of technical efficiency of voluntary counseling and testing of HIV in China. J Peking Univ (Health Sci) 2009; 41:135-140.
26. Guo Z. The direct medical costs analysis of national free anti-retroviral treatment for HIV/AIDS patients. Beijing, China: 2008:69.
27. He Q, Yuan J, Xu Y, Lin P. The projection of HIV/AIDS medical expenses in Guangdong province. China J AIDS/STD 2004; 10:271-274.
28. Xi J. Comparison of working mechanism between methadone maintenance treatment and needle and syringe exchange in Yunnan Province. Beijing, China: China CDC; 2010.
29. Yang H, Li J, Wu Z, Xu L, Wang K. Study on the utilization of health services and costs of hospital-based medical care for 29 patients with HIV/AIDS in China. Chin J Epidemiol 2003; 24:393-396.
30. Zhou F, Li Y, Wang J, Guo Z, xu Y, Yang H, et al. An analysis of direct medical expenditures ralated with free ARV treatment for AIDS patients in part of Yunnan province. Chin J AIDS STD 2008; 14:450-453.
31. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
32. Wang S, Moss JR, Hiller JE. The cost-effectiveness of HIV voluntary counseling and testing in China. Asia Pac J Public Health 2011; 23:620-633.
33. Kretzschmar ME, van der Loeff MF, Coutinho RA. Elimination of HIV by test and treat: a phantom of wishful thinking? AIDS 2012; 26:247-248.
34. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376:285-301.
35. Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report. London, UK: NICE; 2008.
36. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90:1100-1111.
37. Ward J, Mattick RP, Hall W. Methadone maintenance treatment and other opioid replacement therapies. Sydney, Australia: Harwood Academic Publishers; 1998.